Abstract 2392
Background
Despite treatment advances, gastric cancer (GC) remains a leading cause of cancer-related death worldwide. Standard first-line chemotherapeutic regimen for advanced GC consists of fluoropyrimidine with platinum-based combinations, such as capecitabine + oxaliplatin (CAPOX). Recently, CLDN18.2 has emerged as a promising targetable biomarker. In healthy tissue, CLDN18.2 is confined to gastric mucosa tight junctions. Upon malignant transformation, cell polarity perturbations lead to exposure of CLDN18.2 on the cell surface. Zolbetuximab is a chimeric IgG1 monoclonal antibody that specifically binds to CLDN18.2 and mediates cell death through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. In a randomized phase II study (NCT01630083), patients (pts) with CLDN18.2+advanced GC/GEJ treated with zolbetuximab + epirubicin, oxaliplatin, and capecitabine (EOX) showed prolonged survival compared to EOX alone.
Trial design
This global, phase III, double-blind, placebo-controlled study (NCT03653507) will enroll ∼500 adult pts with CLDN18.2+/HER2– locally advanced unresectable or metastatic GC or GEJ not previously treated with chemotherapy for advanced/metastatic disease. Patients will be randomized 1:1 to receive zolbetuximab + CAPOX or placebo + CAPOX. Zolbetuximab will be administered by IV infusion as an 800 mg/m2 loading dose (Cycle 1, Day 1) followed by 600 mg/m2 Q3W in combination with CAPOX. Tumor tissue will be collected at screening to determine CLDN18.2 and HER2 status (if unknown) by central testing; pts will be considered CLDN18.2+ if ≥ 75% of tumor cells demonstrate moderate-to-strong membranous IHC staining. The primary objective is to compare progression-free survival of zolbetuximab + CAPOX vs placebo + CAPOX; secondary efficacy objectives include comparison of overall survival, objective response rate, and duration of response. The safety/tolerability profile, effects on health-related quality-of-life, PK profile, and immunogenicity of zolbetuximab are other secondary endpoints.
Clinical trial identification
NCT03653507.
Editorial acknowledgement
Patrick Tucker of OPEN Health Medical Communications.
Legal entity responsible for the study
Astellas Pharma, Inc.
Funding
Astellas Pharma, Inc.
Disclosure
J.A. Ajani: Advisory / Consultancy, Research grant / Funding (self): Astellas. S. Al-Batran: Advisory / Consultancy: BMS; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Celgene; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Lilly; Advisory / Consultancy: Merck; Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Advisory / Consultancy: Servier; Speaker Bureau / Expert testimony: Nordic Bioscience; Research grant / Funding (institution): Hospira; Research grant / Funding (institution): Medac; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Vifor Pharma; Research grant / Funding (self): Roche Pharma AG. Y. Bang: Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Genentech/Roche; Advisory / Consultancy, Research grant / Funding (institution): MSD; Advisory / Consultancy, Research grant / Funding (institution): Merck Serano; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): BMS; Advisory / Consultancy, Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): GSK; Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Taiho; Advisory / Consultancy: Daiich-Sankyo; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): MacroGenics; Research grant / Funding (institution): Boston Biomedical; Research grant / Funding (institution): FivePrime; Research grant / Funding (institution): Curis; Research grant / Funding (institution): Takeda; Research grant / Funding (institution): Ono; Advisory / Consultancy, Research grant / Funding (institution): Astellas; Advisory / Consultancy, Research grant / Funding (institution): BieGene; Advisory / Consultancy, Research grant / Funding (institution): GreenCross; Advisory / Consultancy, Research grant / Funding (institution): Genexine; Advisory / Consultancy: Samyang Biopharm; Advisory / Consultancy: Hanmi; Research grant / Funding (institution): CKD Pharma. D.V. Catenacci: Advisory / Consultancy: Astellas; Honoraria (self), Advisory / Consultancy: Merck; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self): Gritstone; Honoraria (self), Advisory / Consultancy: Taiho; Honoraria (self), Advisory / Consultancy: Genentech/Roche; Honoraria (self), Advisory / Consultancy: Daiichi Sankyo. P. Enzinger: Advisory / Consultancy: Merck; Advisory / Consultancy: Astellas; Advisory / Consultancy: Celgene; Advisory / Consultancy: Lilly; Advisory / Consultancy: Loxo; Advisory / Consultancy: Taiho. D. Ilson: Advisory / Consultancy: Astellas. S. Kim: Honoraria (self): Merck. F. Lordick: Honoraria (self): Astellas; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self): AstraZeneca; Advisory / Consultancy: Biontech; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self): Elsevier; Travel / Accommodation / Expenses: Infomedica; Honoraria (self): Merck; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self): Servier; Honoraria (self): Amgen; Honoraria (self): Nordic Group; Honoraria (self): Ganymed Pharma; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Fresenius Biotech; Travel / Accommodation / Expenses: Taiho Pharma. K. Shitara: Advisory / Consultancy, Research grant / Funding (institution): Astellas Pharma; Advisory / Consultancy, Research grant / Funding (institution): Eli Lilly; Advisory / Consultancy: BMS; Advisory / Consultancy: Takeda; Advisory / Consultancy: Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (institution): Novartis; Honoraria (institution): AbbVie; Honoraria (institution): Yakult; Research grant / Funding (institution): Dainippon Sumitomo Pharma; Research grant / Funding (institution): Daiichi Sankyo; Research grant / Funding (institution): Taiho Pharmaceutical; Research grant / Funding (institution): Chugai pharma; Advisory / Consultancy, Research grant / Funding (institution): MSD; Research grant / Funding (institution): Medi Science. E. Van Cutsem: Advisory / Consultancy: Astellas; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Boehringer Ingelheim; Advisory / Consultancy, Research grant / Funding (institution): Celgene; Advisory / Consultancy: Incyte; Advisory / Consultancy, Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): Ipsen; Advisory / Consultancy, Research grant / Funding (institution): Merck Sharp & Dohme; Advisory / Consultancy, Research grant / Funding (institution): Merck KGaA; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Roche; Advisory / Consultancy, Research grant / Funding (institution): Servier; Research grant / Funding (institution): Amgen. A. Arozullah: Full / Part-time employment: Astellas Pharma Global Development. J.W. Park: Full / Part-time employment: Astellas Pharma Global Development. All other authors have declared no conflicts of interest.
Resources from the same session
1619 - Meta-analysis of KRAS Mutation as prognostic factor in patients (pts.) with resection of colorectal (CRC) liver metastases: Tumor burden and Sideness analysis.
Presenter: Maria Romina Luca
Session: Poster Display session 2
Resources:
Abstract
2104 - Clinical implications of regorafenib-induced hypothyroidism in metastatic colorectal cancer refractory to standard therapies: A prospective evaluation
Presenter: Jwa Hoon Kim
Session: Poster Display session 2
Resources:
Abstract
2143 - Clinical impact of BRAF V600E mutations in patients (pts) with resectable solitary colorectal liver metastases (CRLM)
Presenter: Shin Kobayashi
Session: Poster Display session 2
Resources:
Abstract
3136 - Trifluridine/tipiracil in metastatic colorectal cancer: an updated multicentre real-world analysis on efficacy, safety and predictive factors.
Presenter: Chara Stavraka
Session: Poster Display session 2
Resources:
Abstract
4234 - Correlation between p53 expression and clinical outcome in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan-cetuximab
Presenter: Eleonora Lai
Session: Poster Display session 2
Resources:
Abstract
4287 - Safety and effectiveness of aflibercept + FOLFIRI for the treatment of patients with metastatic colorectal cancer (mCRC): OZONE secondary analyses
Presenter: Ian Chau
Session: Poster Display session 2
Resources:
Abstract
1820 - A Phase Ib study of the safety and efficacy of atezolizumab (atezo) + bevacizumab (bev) + cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer (mCRC)
Presenter: Johanna Bendell
Session: Poster Display session 2
Resources:
Abstract
5644 - Development and validation of a metastasis-associated immune prognostic model for concurrent metastatic colorectal cancer
Presenter: Zhiwen Luo
Session: Poster Display session 2
Resources:
Abstract
5697 - Prognostic role of blood cell count-based immuno-inflammatory parameters in the Valentino trial
Presenter: Giovanni Fuca
Session: Poster Display session 2
Resources:
Abstract
4704 - Evaluation of safety, immunogenicity and preliminary efficacy of PolyPEPI1018 vaccine in subjects with metastatic colorectal cancer (mCRC) with a predictive biomarker
Presenter: Joleen Hubbard
Session: Poster Display session 2
Resources:
Abstract